Oral Cancer Clinical Trial
Official title:
Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients: A Protocol for Double Blind Randomized Control Trial
Verified date | March 2021 |
Source | China Medical University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Head and neck cancer patients are in high risk to suffer from malnourishment, a risk that increase in postoperative condition and with the use of enteral nutrition (EN). Until now patients who are suffering from indigestion in the ICU received treatment in the form of prokinetic drugs, drags that can lead to serious side effects and only can partially improve digestion. Acupuncture was used successfully in several clinical trials to improve postoperative indigestion in cancer patients without any reported adverse events. This study aims is to design a double blind settings in order to investigate acupuncture effect in combination of prokinetic drugs in the prevention of indigestion in postoperative oral and hypo-pharyngeal cancer patients in the Intensive Care Unit (ICU). Methods: Single center, double blind randomize control trial will compare between two equal groups. A total of 28 patients that will meet the inclusion criteria: Age 30-80, Post plastic surgery for oral cancer or hypo-pharyngeal cancer, Apache score below 20 needed EN. Patients will be randomly divided into specific acupuncture (ACU) or non-specific acupuncture (CON) for 3 treatments in 3 days by a blind acupuncturist along with prokinetic drugs. The main outcome measurement will be the amount of days a patient need to reach Total Energy Expenditure (TEE). Expected outcome: The results will shed light on the effectiveness and safety of acupuncture in a double blind design for posts-surgery ICU cancer patients. In addition, the study presents a revolutionary double blind design that if will prove as successful might influence the way double blind acupuncture studies are performed today.
Status | Completed |
Enrollment | 28 |
Est. completion date | March 19, 2021 |
Est. primary completion date | March 19, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age 30-80 - Apache score below 20 - Patients needed EN - Post plastic surgery, including oral cancer or hypo-pharyngeal cancer Exclusion Criteria: - Coagulopathy, - prolong prothrombin time (PPT) activated partial thromboplastin time (aPTT) more then 4 times - Thrombocytopenia - low platelet count - Clinically unstable: receiving two inotropic agents or Fraction of inspired Oxygen (FiO2) >70% - Estimated ICU stay - less than 3 days |
Country | Name | City | State |
---|---|---|---|
Taiwan | surgical and burn intensive care departments and the plastic surgical department of China Medical University Hospital in Taichung city, Taiwan. | Taichung City | Taichung |
Lead Sponsor | Collaborator |
---|---|
China Medical University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to reach Total Energy Expenditure | Number of days in takes for each patient to achieve the Total Energy Expenditure | Up to 1 month | |
Secondary | Amount of prokinetic drugs prescribed | Secondary outcomes measures are the amount of prokinetic drugs prescribed by the ICU doctor in total dosage | Up to 1 month | |
Secondary | The need of naso-jejunal feeding tube | After 5 days of conservative treatment for the poor digestion (naso-gastric tube drainage of more than 500ml per day or severe diarrhea of more than 1000 ml per day) | Up to 1 month | |
Secondary | The need of parental nutrition | In patients who cannot digest with daily naso-gastric tube drainage of more than 500ml per day or severe diarrhea of more than 1000 ml per day | up to 1 month | |
Secondary | Incidents of vomits | Incidents of vomits in total number of times and volume in micro liters | Up to 1 month | |
Secondary | Albumin blood levels | Patient's Albumin blood levels will help to assets patient's nutrition status | Up to 1 month | |
Secondary | Total ICU stay | Total ICU stay in days | Up to 23 month | |
Secondary | Total hospital stay | Total hospital stay in days | Up to 23 month | |
Secondary | Total mechanical ventilation in days | A day of mechanical ventilation is at least 6 hours of mechanical ventilation in one day | Up to 23 month | |
Secondary | Total mortality | In case of mortality ,total mortality will be compered between the two groups | Up to 23 month | |
Secondary | Incidents of diarrhea | Incidents of diarrhea in number of times and volume in micro liters | Up to 1 month | |
Secondary | Incidents of constipation | No stool passage in 3 days will be considered as constipation | Up to 1 month | |
Secondary | Incidents of nausea | Incidents of nausea in number of times , measured by patient complains | Up to 1 month | |
Secondary | Incidents of gastrointestinal bleeding | Positive occult blood test of the naso-gastric tube drainage and in the stool | Up to 1 month | |
Secondary | Incidents of fever episodes | Body temperature more than 38 degrees Celsius | Up to 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Completed |
NCT00158678 -
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
|
Phase 3 | |
Completed |
NCT00933387 -
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT05030597 -
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Recruiting |
NCT03684707 -
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
|
Phase 4 | |
Recruiting |
NCT06130332 -
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
|
Phase 2 | |
Recruiting |
NCT04372914 -
Prevention of Oral DNA Damage by Black Raspberries
|
N/A | |
Active, not recruiting |
NCT03529422 -
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
|
Phase 2 | |
Recruiting |
NCT03686020 -
Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)
|
||
Not yet recruiting |
NCT06060288 -
Diagnostic Accuracy of Mobile Phone Imaging Compared to Conventional Clinical Examination for Oral Cancer Screening
|
||
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01418118 -
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
|
Phase 4 | |
Active, not recruiting |
NCT00232960 -
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Completed |
NCT04614896 -
Use of Ultrasound for Measuring Size of Oral Tongue Cancers
|
N/A | |
Recruiting |
NCT03685409 -
Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
|
Phase 3 | |
Completed |
NCT00402779 -
Erlotinib Prevention of Oral Cancer (EPOC)
|
Phase 3 | |
Recruiting |
NCT05153733 -
Improved Implant for Reconstruction Purposes After Mandibular Resection
|
N/A |